-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Star Enterprise of Chemical Machinery and Equipment Network ] Pharmaceutical equipment is the upstream of the pharmaceutical industry and plays a pivotal role in pharmaceutical production.
It belongs to the field of industrial policy support.
According to different types, pharmaceutical equipment can be divided into general equipment and *equipment.
General equipment mainly includes drying equipment , separation equipment, extraction and concentration equipment, crushing equipment, mixing equipment, etc.
*equipment includes oral liquid production line and capsule production line , Decoction Pieces Machinery, etc.
Since 2020, what is the development status of my country's pharmaceutical equipment industry? May wish to find the answer from the three quarterly reports and annual performance forecasts disclosed by major listed pharmaceutical companies.
Chemical machinery equipment network star enterprise chemical machinery equipment pharmaceutical equipment drying equipmentIt belongs to the field of industrial policy support.
According to different types, pharmaceutical equipment can be divided into general equipment and *equipment.
General equipment mainly includes drying equipment , separation equipment, extraction and concentration equipment, crushing equipment, mixing equipment, etc.
*equipment includes oral liquid production line and capsule production line , Decoction Pieces Machinery, etc.
Since 2020, what is the development status of my country's pharmaceutical equipment industry? May wish to find the answer from the three quarterly reports and annual performance forecasts disclosed by major listed pharmaceutical companies.
On October 31, Xinhua Medical released its third quarter report for 2020, showing that the company achieved operating income of 6.
532 billion yuan in the first nine months, a year-on-year increase of 3.
43%, and net profit attributable to shareholders of listed companies was 213 million yuan, a year-on-year decrease of 73.
45%.
At the same time, the company also released a 2020 full-year performance forecast, and it is expected that the net profit attributable to shareholders of listed companies in 2020 will increase by about 175.
22% year-on-year.
The 2019 annual report shows that Xinhua Medical's main business mainly includes medical equipment, pharmaceutical equipment, and medical services, accounting for 79.
19%, 12.
23%, and 6.
89% of revenue respectively.
Xinhua Medical mentioned on the interactive platform in August that the number of orders for the company's pharmaceutical equipment sector in 2020 has increased, and its performance is gradually improving.
532 billion yuan in the first nine months, a year-on-year increase of 3.
43%, and net profit attributable to shareholders of listed companies was 213 million yuan, a year-on-year decrease of 73.
45%.
At the same time, the company also released a 2020 full-year performance forecast, and it is expected that the net profit attributable to shareholders of listed companies in 2020 will increase by about 175.
22% year-on-year.
The 2019 annual report shows that Xinhua Medical's main business mainly includes medical equipment, pharmaceutical equipment, and medical services, accounting for 79.
19%, 12.
23%, and 6.
89% of revenue respectively.
Xinhua Medical mentioned on the interactive platform in August that the number of orders for the company's pharmaceutical equipment sector in 2020 has increased, and its performance is gradually improving.
Tofflon is in a position in the field of freeze-drying.
The company expects the net profit attributable to shareholders of listed companies in the first nine months of 2020 to be 279 million to 297 million yuan.
During the reporting period, the company focused on the development strategy of “systematization, digitization, and digitization”, actively responded to customer needs, and effectively guaranteed the completion of the system project delivery plan; maintained effective communication with customers through online methods, and focused on the science of pharmaceutical manufacturing and pharmaceutical machinery.
Scientific manufacturing for technical cooperation and exchanges; continuous implementation of precise management concepts, implementation of digital transformations, and improved cost control; at the same time, the company’s new products and new markets in various business segments over the years have gradually shown results, and the estimated net profit attributable to shareholders of listed companies An increase of 360%-390% in the same period last year.
The company expects the net profit attributable to shareholders of listed companies in the first nine months of 2020 to be 279 million to 297 million yuan.
During the reporting period, the company focused on the development strategy of “systematization, digitization, and digitization”, actively responded to customer needs, and effectively guaranteed the completion of the system project delivery plan; maintained effective communication with customers through online methods, and focused on the science of pharmaceutical manufacturing and pharmaceutical machinery.
Scientific manufacturing for technical cooperation and exchanges; continuous implementation of precise management concepts, implementation of digital transformations, and improved cost control; at the same time, the company’s new products and new markets in various business segments over the years have gradually shown results, and the estimated net profit attributable to shareholders of listed companies An increase of 360%-390% in the same period last year.
The third quarter report disclosed by Chutian Technology, which is also a domestic pharmaceutical equipment, shows that the company achieved total operating income of 1.
34 billion in the first three quarters of 2020, a year-on-year increase of 1.
7%; and achieved a net profit of 46.
376 million attributable to the parent, a year-on-year increase of 106.
3%.
During the period, operating cash flow increased significantly by 896.
8% to 290 million, mainly due to the increase in new orders during the reporting period.
It is worth mentioning that during the reporting period, Chutian also increased the capital of Chutian Asset Management by 320 million yuan to complete the acquisition of the remaining 24.
9% of the Romaco company held by the German DBAG Fund.
This also means that Chutian will Romaco company this time.
The whole is loaded into the listed company.
34 billion in the first three quarters of 2020, a year-on-year increase of 1.
7%; and achieved a net profit of 46.
376 million attributable to the parent, a year-on-year increase of 106.
3%.
During the period, operating cash flow increased significantly by 896.
8% to 290 million, mainly due to the increase in new orders during the reporting period.
It is worth mentioning that during the reporting period, Chutian also increased the capital of Chutian Asset Management by 320 million yuan to complete the acquisition of the remaining 24.
9% of the Romaco company held by the German DBAG Fund.
This also means that Chutian will Romaco company this time.
The whole is loaded into the listed company.
Canaan Technology achieved total operating income of 600 million in the first three quarters of 2020, a year-on-year increase of 68.
3%; realized a net profit of 52.
138 million attributable to the parent, a year-on-year increase of 56.
8%, and a period expense ratio of 20.
6%, a year-on-year decrease of 11.
6%.
Expense control*.
Canaan Technology is a domestic solid preparation smart factory overall solution provider.
In 2020, the company will focus on the "solid preparation smart factory overall solution supplier" and the strategic layout of the big health industry, and continue to deepen the pharmaceutical equipment market and smart logistics industry.
Among them, in the field of pharmaceutical equipment, in the field of solid preparation equipment, the domestic market is mainly occupied by some manufacturers in Germany and Italy.
The middle and low-end market is mainly dominated by domestic manufacturers through price wars, and the degree of competition is fierce.
In order to improve the core advantages of pharmaceutical equipment manufacturing, Canaan Technology has made frequent actions since this year, including foreign investment and establishment of wholly-owned subsidiaries, participation in bidding for the use of state-owned construction land in Yongjia County 202006, etc.
, to strengthen the core competitiveness of the business sector and further expand the company's business scale .
3%; realized a net profit of 52.
138 million attributable to the parent, a year-on-year increase of 56.
8%, and a period expense ratio of 20.
6%, a year-on-year decrease of 11.
6%.
Expense control*.
Canaan Technology is a domestic solid preparation smart factory overall solution provider.
In 2020, the company will focus on the "solid preparation smart factory overall solution supplier" and the strategic layout of the big health industry, and continue to deepen the pharmaceutical equipment market and smart logistics industry.
Among them, in the field of pharmaceutical equipment, in the field of solid preparation equipment, the domestic market is mainly occupied by some manufacturers in Germany and Italy.
The middle and low-end market is mainly dominated by domestic manufacturers through price wars, and the degree of competition is fierce.
In order to improve the core advantages of pharmaceutical equipment manufacturing, Canaan Technology has made frequent actions since this year, including foreign investment and establishment of wholly-owned subsidiaries, participation in bidding for the use of state-owned construction land in Yongjia County 202006, etc.
, to strengthen the core competitiveness of the business sector and further expand the company's business scale .
Since the beginning of the year, the sales volume of the sterilization products of Tailin Biological has increased, which led to an increase in the overall sales revenue in the first quarter.
It achieved revenue of 40.
755 million yuan, an increase of 3.
62% year-on-year; the net profit attributable to shareholders of listed companies was 7,347,300 yuan, an increase of 45.
69% year-on-year .
Since the second half of the year, the company's performance has continued to grow.
The company's 2020 third quarterly report released on October 30 showed that in the first nine months it achieved operating income of 134 million yuan, an increase of 8.
80% year-on-year, and the net profit attributable to shareholders of listed companies was 32.
695 million yuan, an increase of 29.
07% year-on-year.
The company's main business is the research and development, manufacturing and sales of microbial detection and control technology system products, organic matter analysis instruments and other pharmaceutical equipment.
It achieved revenue of 40.
755 million yuan, an increase of 3.
62% year-on-year; the net profit attributable to shareholders of listed companies was 7,347,300 yuan, an increase of 45.
69% year-on-year .
Since the second half of the year, the company's performance has continued to grow.
The company's 2020 third quarterly report released on October 30 showed that in the first nine months it achieved operating income of 134 million yuan, an increase of 8.
80% year-on-year, and the net profit attributable to shareholders of listed companies was 32.
695 million yuan, an increase of 29.
07% year-on-year.
The company's main business is the research and development, manufacturing and sales of microbial detection and control technology system products, organic matter analysis instruments and other pharmaceutical equipment.
Concluding remarks
Overall, with the rapid development of the pharmaceutical industry this year, the demand for pharmaceutical equipment in the pharmaceutical equipment market has continued to expand, and the number of orders from industry companies has increased significantly, which has led to continuous improvement in performance.
At the same time, in the face of increasingly fierce market competition, the major pharmaceutical machinery companies frequently took new actions during the year, including acquisitions, establishment of subsidiaries, deployment of new products and new markets, etc.
The problems in cost management and control have also caused more pharmaceutical machinery companies.
Attention.
In addition, from the perspective of industry development trends, the domestic pharmaceutical equipment industry is seriously lacking in the market.
This year, pharmaceutical machinery companies including Canaan Technology are making efforts in the field, which will drive the further transformation and upgrading of the domestic pharmaceutical equipment industry.
At the same time, in the face of increasingly fierce market competition, the major pharmaceutical machinery companies frequently took new actions during the year, including acquisitions, establishment of subsidiaries, deployment of new products and new markets, etc.
The problems in cost management and control have also caused more pharmaceutical machinery companies.
Attention.
In addition, from the perspective of industry development trends, the domestic pharmaceutical equipment industry is seriously lacking in the market.
This year, pharmaceutical machinery companies including Canaan Technology are making efforts in the field, which will drive the further transformation and upgrading of the domestic pharmaceutical equipment industry.
Original title: Development status of the pharmaceutical equipment industry in 2020: Significant increase in orders and continuous improvement in performance
